Skip to content
HowShorted

Alaunos Therapeutics, Inc. short interest in 2023

In 2023, Alaunos Therapeutics, Inc.'s disclosed short interest ran from 11.19% of shares outstanding on 13 Jan 2023 to 11.23% on 29 Dec 2023, a change of +0.04 percentage points. The year's high was 11.23% on 29 Dec 2023 and its low 9.30% on 15 Nov 2023, averaging 10.25% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 74.88 days on 14 Jul 2023. Full history: Alaunos Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Alaunos Therapeutics, Inc. in 2023

2023 in figures

Start of year
11.19% (13 Jan 2023)
End of year
11.23% (29 Dec 2023)
Change
+0.04 pp
High
11.23% (29 Dec 2023)
Low
9.30% (15 Nov 2023)
Average
10.25%
Highest days to cover
74.88 (14 Jul 2023)
SEC filings marked
8

Every report in 2023

Alaunos Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202311.19%17.24
31 Jan 202311.14%38.22
15 Feb 202310.89%36.26
28 Feb 202310.90%34.25
15 Mar 20239.60%24.2010-K filed, results (8-K)
31 Mar 20239.77%32.55
14 Apr 20239.88%60.42
28 Apr 20239.92%46.49
15 May 20239.90%49.2010-Q filed, results (8-K)
31 May 202310.37%32.64
15 Jun 202310.63%50.51
30 Jun 202310.74%41.66
14 Jul 202310.73%74.88
31 Jul 202310.86%62.04
15 Aug 202310.68%10.4510-Q filed, results (8-K)
31 Aug 202310.09%4.32
15 Sep 20239.82%17.79
29 Sep 20239.62%15.43
13 Oct 20239.63%14.04
31 Oct 20239.99%5.87
15 Nov 20239.30%4.1510-Q filed, results (8-K)
30 Nov 20239.84%5.07
15 Dec 20239.35%6.54
29 Dec 202311.23%2.05

See also: Alaunos Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.